Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

(2020) Rajen Mody et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal antibody extravasations: Two case reports and literature review

(2020) Alicia Rodríguez-Alarcón et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Current management of neuroblastoma and future direction

(2019) Elizabeth R. Pastor et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

(2017) Thorsten Simon et al.   KLINISCHE PADIATRIE

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

(2017) Rajen Mody et al.   LANCET ONCOLOGY

Neuroblastoma

(2016) Katherine K. Matthay et al.   Nature Reviews Disease Primers

A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity

(2011) Nidia Alvarez-Rueda et al.   PLoS One

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia

(2010) Linda S. Sorkin et al.   PAIN